Skip to main content

Articles

Page 2 of 27

  1. Although research on the effects of comorbidities on coronavirus disease 2019 (COVID-19) patients is increasing, the risk of cancer history has not been evaluated for the mortality of patients with COVID-19.

    Authors: Yifan Meng, Wanrong Lu, Ensong Guo, Jia Liu, Bin Yang, Ping Wu, Shitong Lin, Ting Peng, Yu Fu, Fuxia Li, Zizhuo Wang, Yuan Li, Rourou Xiao, Chen Liu, Yuhan Huang, Funian Lu…

    Citation: Journal of Hematology & Oncology 2020 13:75

    Content type: Research

    Published on:

  2. Melanoma patients who have detectable serum soluble NKG2D ligands either at the baseline or post-treatment of PD1/PDL1 blockade exhibit poor overall survival. Among families of soluble human NKG2D ligands, the...

    Authors: Fahmin Basher, Payal Dhar, Xin Wang, Derek A. Wainwright, Bin Zhang, Jeffrey Sosman, Zhe Ji and Jennifer D. Wu

    Citation: Journal of Hematology & Oncology 2020 13:74

    Content type: Research

    Published on:

  3. Here we apply state-of-the-art CRISPR technologies to study the impact that PTENP1 pseudogene transcript has on the expression levels of its parental gene PTEN, and hence on the output of AKT signaling in cancer....

    Authors: Marianna Vitiello, Monica Evangelista, Yang Zhang, Leonardo Salmena, Pier Paolo Pandolfi and Laura Poliseno

    Citation: Journal of Hematology & Oncology 2020 13:73

    Content type: Rapid communication

    Published on:

  4. Acute myeloid leukemia (AML) is a common leukemia subtype and has a poor prognosis. The risk of AML is highly related to age. In the context of population aging, a comprehensive report presenting epidemiologic...

    Authors: Ming Yi, Anping Li, Linghui Zhou, Qian Chu, Yongping Song and Kongming Wu

    Citation: Journal of Hematology & Oncology 2020 13:72

    Content type: Research

    Published on:

  5. Rituximab (R) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) is the current standard therapy for diffuse large B cell lymphoma (DLBCL). Obinutuzumab (G), a glycoengineered, type II anti...

    Authors: Laurie H. Sehn, Maurizio Martelli, Marek Trněný, Wenxin Liu, Christopher R. Bolen, Andrea Knapp, Deniz Sahin, Gila Sellam and Umberto Vitolo

    Citation: Journal of Hematology & Oncology 2020 13:71

    Content type: Rapid communication

    Published on:

  6. Recent years have witnessed major advances that have improved outcome of adults with acute lymphoblastic leukemia (ALL). The emergence of the concept of measurable residual disease has fine-tuned our prognosti...

    Authors: Bachar Samra, Elias Jabbour, Farhad Ravandi, Hagop Kantarjian and Nicholas J. Short

    Citation: Journal of Hematology & Oncology 2020 13:70

    Content type: Review

    Published on:

  7. The life expectancy of extensive-stage small cell lung (ES-SCLC) cancer patients has not improved in the last 2–3 decades until two recent trials (CASPIAN and IMpower133) showing the addition of anti-programme...

    Authors: Chengliang Huang, Gregory N. Gan and Jun Zhang

    Citation: Journal of Hematology & Oncology 2020 13:69

    Content type: Letter to the Editor

    Published on:

  8. CD8+ T cell trafficking to the tumor site is essential for effective colorectal cancer (CRC) immunotherapy. However, the mechanism underlying CD8+ T cell infiltration in colorectal tumor tissues is not fully unde...

    Authors: Dan Wang, Weina Yu, Jingyao Lian, Qian Wu, Shasha Liu, Li Yang, Feng Li, Lan Huang, Xinfeng Chen, Zhen Zhang, Aitian Li, Jinbo Liu, Zhenqiang Sun, Junxia Wang, Weitang Yuan and Yi Zhang

    Citation: Journal of Hematology & Oncology 2020 13:68

    Content type: Research

    Published on:

  9. Ibrutinib is a Bruton tyrosine kinase inhibitor approved for the treatment of chronic lymphocytic leukemia (CLL) in 2014. Ibrutinib is often used to treat patients who are younger than the patients originally ...

    Authors: Camille Hardy-Abeloos, Rachel Pinotti and Janice Gabrilove

    Citation: Journal of Hematology & Oncology 2020 13:66

    Content type: Review

    Published on:

  10. Insulin-like growth factors (IGFs) play important roles in mammalian growth, development, aging, and diseases. Aberrant IGFs signaling may lead to malignant transformation and tumor progression, thus providing...

    Authors: Hui Hua, Qingbin Kong, Jie Yin, Jin Zhang and Yangfu Jiang

    Citation: Journal of Hematology & Oncology 2020 13:64

    Content type: Review

    Published on:

  11. Here, we report a unique acute myeloid leukemia (AML) bone marrow-derived mesenchymal stem cell (MSC) with both mesenchymal and endothelial potential, which we have named Mesenchymal Cancer Stem Cells (MCSCs)....

    Authors: Huynh Cao, Jeffrey Xiao, Mark E. Reeves, Kimberly Payne, Chien Shing Chen, David J. Baylink, Guido Marcucci and Yi Xu

    Citation: Journal of Hematology & Oncology 2020 13:63

    Content type: Letter to the Editor

    Published on:

  12. Expression of Oct4 maintains cancer stem cell (CSC)-like properties in lung cancer cells and is correlated with poor prognosis of lung adenocarcinoma. M2-type tumor-associated macrophages (TAMs) promote cancer...

    Authors: Chia-Sing Lu, Ai-Li Shiau, Bing-Hua Su, Tsui-Shan Hsu, Chung-Teng Wang, Yu-Chu Su, Ming-Shian Tsai, Yin-Hsun Feng, Yau-Lin Tseng, Yi-Ting Yen, Chao-Liang Wu and Gia-Shing Shieh

    Citation: Journal of Hematology & Oncology 2020 13:62

    Content type: Research

    Published on:

  13. Cellular homeostasis requires the proper nuclear-cytoplasmic partitioning of large molecules, which is often deregulated in cancer. XPO1 is an export receptor responsible for the nuclear-cytoplasmic transport ...

    Authors: Nancy G. Azizian and Yulin Li

    Citation: Journal of Hematology & Oncology 2020 13:61

    Content type: Review

    Published on:

  14. Cancer stem cells (CSCs) contribute to the initiation, recurrence, and metastasis of cancer; however, there are still no drugs targeting CSCs in clinical application. There are several signaling pathways playi...

    Authors: Yue Yang, Xiaoman Li, Ting Wang, Qianqian Guo, Tao Xi and Lufeng Zheng

    Citation: Journal of Hematology & Oncology 2020 13:60

    Content type: Review

    Published on:

  15. Advanced non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with a poor prognosis and no known cure. Survival time is often short because of limited treatment options. Recent advances i...

    Authors: Ruqin Chen, Rami Manochakian, Lauren James, Abdel-Ghani Azzouqa, Huashan Shi, Yan Zhang, Yujie Zhao, Kexun Zhou and Yanyan Lou

    Citation: Journal of Hematology & Oncology 2020 13:58

    Content type: Review

    Published on:

  16. Gastrointestinal cancer, the most common solid tumor, has a poor prognosis. With the development of high-throughput sequencing and detection technology, recent studies have suggested that many chemical modific...

    Authors: Qiang Wang, Wei Geng, Huimin Guo, Zhangding Wang, Kaiyue Xu, Chen Chen and Shouyu Wang

    Citation: Journal of Hematology & Oncology 2020 13:57

    Content type: Review

    Published on:

  17. Peripheral T cell lymphomas form a heterogeneous group with a usually dismal prognostic. The place of allogeneic stem cell transplantation to treat PTCL is debated.

    Authors: Anne-Claire Mamez, Axelle Dupont, Didier Blaise, Patrice Chevallier, Edouard Forcade, Patrice Ceballos, Mohamad Mohty, Felipe Suarez, Yves Beguin, Regis Peffault De Latour, Marie-Thérèse Rubio, Olivier Tournilhac and Stéphanie Nguyen

    Citation: Journal of Hematology & Oncology 2020 13:56

    Content type: Research

    Published on:

  18. Immune checkpoint inhibitors, especially the programmed cell death receptor-1/ligand 1 (PD-1/L1) inhibitors, displayed promising efficacy in several solid tumor types and hematological malignancies. Data relat...

    Authors: Antoine Italiano, Carine Bellera and Sandra D’Angelo

    Citation: Journal of Hematology & Oncology 2020 13:55

    Content type: Letter to the Editor

    Published on:

  19. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Hanren Dai, Zhiqiang Wu, Hejin Jia, Chuan Tong, Yelei Guo, Dongdong Ti, Xiao Han, Yang Liu, Wenying Zhang, Chunmeng Wang, Yajing Zhang, Meixia Chen, Qingming Yang, Yao Wang and Weidong Han

    Citation: Journal of Hematology & Oncology 2020 13:53

    Content type: Correction

    Published on:

    The original article was published in Journal of Hematology & Oncology 2020 13:30

  20. Human leukocyte antigen (HLA) haploidentical stem cell transplantation (haplo-SCT) as a postremission treatment for standard risk Philadelphia chromosome-negative acute lymphoblastic leukemia (SR Ph-ALL) in th...

    Authors: Meng Lv, Qian Jiang, Dao-Bin Zhou, Yu Hu, Dai-Hong Liu, De-Pei Wu, Jing-Bo Wang, Hao Jiang, Jing Wang, Ying-jun Chang, Yu Wang, Xiao-Hui Zhang, Lan-Ping Xu, Kai-Yan Liu and Xiao-Jun Huang

    Citation: Journal of Hematology & Oncology 2020 13:52

    Content type: Letter to the Editor

    Published on:

  21. Authors: Shen Zhao, Hongyun Zhao, Cheng Lv, Jifang Gong, Jian Zhang, Wenfeng Fang, Jin Li, Xichun Hu, Yi Ba, Binghe Xu, Yanqiao Zhang, Yun Fan, Kunyan Li, Xiaoyuan Chen, Zhimin Yang, Lin Shen…

    Citation: Journal of Hematology & Oncology 2020 13:51

    Content type: Editorial

    Published on:

  22. In this nationwide, population-based study, we assessed 10-year relative survival among 225,305 patients with ten early-stage cancers diagnosed in the Netherlands during 2004–2015. This study aimed to ascertai...

    Authors: Avinash G. Dinmohamed, Valery E. P. P. Lemmens, Ignace H. J. T. de Hingh and Otto Visser

    Citation: Journal of Hematology & Oncology 2020 13:49

    Content type: Letter to the Editor

    Published on:

  23. Bruton tyrosine kinase (BTK) inhibitors have demonstrated a high degree of efficacy in the treatment of B cell malignancies characterized by constitutive B cell receptor activation, including chronic lymphocyt...

    Authors: Wei Xu, Shenmiao Yang, Keshu Zhou, Ling Pan, Zengjun Li, Jianfeng Zhou, Sujun Gao, Daobin Zhou, Jianda Hu, Ru Feng, Haiwen Huang, Meng Ji, Haiyi Guo, Jane Huang, William Novotny, Shibao Feng…

    Citation: Journal of Hematology & Oncology 2020 13:48

    Content type: Research

    Published on:

  24. Association of immune-related adverse events with tumor response has been reported. Reactive cutaneous capillary endothelial proliferation (RCCEP) is the most common adverse event related to camrelizumab, an i...

    Authors: Feng Wang, Shukui Qin, Xinchen Sun, Zhenggang Ren, Zhiqiang Meng, Zhendong Chen, Xiaoli Chai, Jianping Xiong, Yuxian Bai, Lin Yang, Hong Zhu, Weijia Fang, Xiaoyan Lin, Xiaoming Chen, Enxiao Li, Linna Wang…

    Citation: Journal of Hematology & Oncology 2020 13:47

    Content type: Research

    Published on:

  25. The use of post-transplant cyclophosphamide (PTCy) is highly effective in preventing graft-versus-host disease (GVHD) in the haploidentical (Haplo) transplant setting and is being increasingly used in matched ...

    Authors: Jaime Sanz, Jacques-Emmanuel Galimard, Myriam Labopin, Boris Afanasyev, Emanuele Angelucci, Fabio Ciceri, Didier Blaise, Jan J. Cornelissen, Ellen Meijer, J. L. Diez-Martin, Yener Koc, Montserrat Rovira, Luca Castagna, Bipin Savani, Annalisa Ruggeri, Arnon Nagler…

    Citation: Journal of Hematology & Oncology 2020 13:46

    Content type: Research

    Published on:

  26. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Yang Liu, Li-Li Lu, Duo Wen, Dong-Li Liu, Li-Li Dong, Dong-Mei Gao, Xin-Yu Bian, Jian Zhou, Jia Fan and Wei-Zhong Wu

    Citation: Journal of Hematology & Oncology 2020 13:44

    Content type: Correction

    Published on:

    The original article was published in Journal of Hematology & Oncology 2020 13:12

  27. The novel coronavirus (2019-nCoV) is an emerging causative agent that was first described in late December 2019 and causes a severe respiratory infection in humans. Notably, many of affected patients of COVID-...

    Authors: Peiwei Chai, Jie Yu, Shengfang Ge, Renbing Jia and Xianqun Fan

    Citation: Journal of Hematology & Oncology 2020 13:43

    Content type: Letter to the Editor

    Published on:

  28. Consolidative allogeneic hematopoietic stem cell transplantation is a controversial option for patients with relapsed/refractory acute lymphoblastic leukemia after chimeric antigen receptor T cell (CAR-T) ther...

    Authors: Houli Zhao, Jieping Wei, Guoqing Wei, Yi Luo, Jimin Shi, Qu Cui, Mingfeng Zhao, Aibin Liang, Qing Zhang, Jianmin Yang, Xin Li, Jing Chen, Xianmin Song, Hongmei Jing, Yuhua Li, Siguo Hao…

    Citation: Journal of Hematology & Oncology 2020 13:42

    Content type: Rapid communication

    Published on:

  29. Aberrant activation of DNA damage response (DDR) is a major cause of chemoresistance in colorectal cancer (CRC). CHK1 is upregulated in CRC and contributes to therapeutic resistance. We investigated the upstre...

    Authors: Xinfang Yu, Wei Li, Haidan Liu, Qipan Deng, Xu Wang, Hui Hu, Zijun Y. Xu-Monette, Wei Xiong, Zhongxin Lu, Ken H. Young, Wei Wang and Yong Li

    Citation: Journal of Hematology & Oncology 2020 13:40

    Content type: Research

    Published on:

  30. Ovarian cancer is one of the most lethal gynecologic malignancies reported throughout the world. The initial, standard-of-care, adjuvant chemotherapy in epithelial ovarian cancer is usually a platinum drug, su...

    Authors: Patrycja Gralewska, Arkadiusz Gajek, Agnieszka Marczak and Aneta Rogalska

    Citation: Journal of Hematology & Oncology 2020 13:39

    Content type: Review

    Published on:

  31. Rituximab in combination with chemotherapy has shown efficacy in patients with diffuse large B-cell lymphoma (DLBCL) for more than 15 years. HLX01 was developed as the rituximab biosimilar following a stepwise...

    Authors: Yuankai Shi, Yongping Song, Yan Qin, Qingyuan Zhang, Xiaohong Han, Xiaonan Hong, Dong Wang, Wei Li, Yang Zhang, Jifeng Feng, Jianmin Yang, Huilai Zhang, Chuan Jin, Yu Yang, Jianda Hu, Zhao Wang…

    Citation: Journal of Hematology & Oncology 2020 13:38

    Content type: Letter to the Editor

    Published on:

  32. Rearranged during transfection (RET) has been proven to be a tumorigenic target in non-small cell lung cancers (NSCLCs). In RET-rearranged NSCLCs, molecular features and their impact on prognosis were not well il...

    Authors: Chang Lu, Xiao-Rong Dong, Jun Zhao, Xu-Chao Zhang, Hua-Jun Chen, Qing Zhou, Hai-Yan Tu, Xing-Hao Ai, Xiao-Feng Chen, Gai-Li An, Jun Bai, Jin-Lu Shan, Yi-Na Wang, Shuan-Ying Yang, Xiang Liu, Wu Zhuang…

    Citation: Journal of Hematology & Oncology 2020 13:37

    Content type: Research

    Published on:

  33. Current acute myeloid leukemia (AML) therapy fails to eliminate quiescent leukemic blasts in the bone marrow, leading to about 50% of patient relapse by increasing AML burden in the bone marrow, blood, and ext...

    Authors: Victor Pallarès, Ugutz Unzueta, Aïda Falgàs, Laura Sánchez-García, Naroa Serna, Alberto Gallardo, Gordon A. Morris, Lorena Alba-Castellón, Patricia Álamo, Jorge Sierra, Antonio Villaverde, Esther Vázquez, Isolda Casanova and Ramon Mangues

    Citation: Journal of Hematology & Oncology 2020 13:36

    Content type: Research

    Published on:

  34. N6-methyladenosine (m6A) is a well-known post-transcriptional modification that is the most common type of methylation in eukaryotic mRNAs. The regulation of m6A is dynamic and reversible, which is erected by m6A...

    Authors: Yanchun Zhao, Yuanfei Shi, Huafei Shen and Wanzhuo Xie

    Citation: Journal of Hematology & Oncology 2020 13:35

    Content type: Review

    Published on:

  35. Abl interactor 1 (Abi1) is a downstream target of Abl tyrosine kinases and a component of the WAVE regulatory complex (WRC) that plays an important role in regulating actin cytoskeleton remodeling and membrane...

    Authors: James Faulkner, Peixin Jiang, Delaney Farris, Ryan Walker and Zonghan Dai

    Citation: Journal of Hematology & Oncology 2020 13:34

    Content type: Research

    Published on:

  36. Soft-tissue sarcomas represent a heterogeneous group of diseases with distinct genetic and clinical features accounting for up to 1% of cancer in adults and 15% of cancer in children. Epithelioid sarcoma is an...

    Authors: Antoine Italiano

    Citation: Journal of Hematology & Oncology 2020 13:33

    Content type: Editorial

    Published on:

  37. In the search for novel antibody-drug conjugates (ADCs) with therapeutic potential, it is imperative to identify novel targets to direct the antibody moiety. CD13 seems an attractive ADC target as it shows a d...

    Authors: Juan Manuel Domínguez, Gema Pérez-Chacón, María José Guillén, María José Muñoz-Alonso, Beatriz Somovilla-Crespo, Danay Cibrián, Bárbara Acosta-Iborra, Magdalena Adrados, Cecilia Muñoz-Calleja, Carmen Cuevas, Francisco Sánchez-Madrid, Pablo Avilés and Juan M. Zapata

    Citation: Journal of Hematology & Oncology 2020 13:32

    Content type: Rapid communication

    Published on:

  38. Hematopoietic stem cell (HSC) aging, which is accompanied by reduced self-renewal ability, impaired homing, myeloid-biased differentiation, and other defects in hematopoietic reconstitution function, is a hot ...

    Authors: Xia Li, Xiangjun Zeng, Yulin Xu, Binsheng Wang, Yanmin Zhao, Xiaoyu Lai, Pengxu Qian and He Huang

    Citation: Journal of Hematology & Oncology 2020 13:31

    Content type: Review

    Published on:

  39. Despite the impressive complete remission (CR) induced by CD19 CAR-T cell therapy in B-ALL, the high rate of complete responses is sometimes limited by the emergence of CD19-negative leukemia. Bispecific CAR-m...

    Authors: Hanren Dai, Zhiqiang Wu, Hejin Jia, Chuan Tong, Yelei Guo, Dongdong Ti, Xiao Han, Yang Liu, Wenying Zhang, Chunmeng Wang, Yajing Zhang, Meixia Chen, Qingming Yang, Yao Wang and Weidong Han

    Citation: Journal of Hematology & Oncology 2020 13:30

    Content type: Rapid communication

    Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2020 13:53

  40. Cancer immunotherapy has reached a critical point, now that immune checkpoint inhibitors and two CAR-T products have received market approval in treating 16 types of cancers and 1 tissue-agnostic cancer indica...

    Authors: Chongxian Pan, Hongtao Liu, Elizabeth Robins, Wenru Song, Delong Liu, Zihai Li and Lei Zheng

    Citation: Journal of Hematology & Oncology 2020 13:29

    Content type: Review

    Published on:

  41. Immunotherapy with immune checkpoint inhibitors (ICIs) for solid tumors had significantly improved overall survival. This type of therapy is still not available for acute myeloid leukemia (AML). One major issu...

    Authors: Cunte Chen, Chaofeng Liang, Shunqing Wang, Chi Leong Chio, Yuping Zhang, Chengwu Zeng, Shaohua Chen, Caixia Wang and Yangqiu Li

    Citation: Journal of Hematology & Oncology 2020 13:28

    Content type: Letter to the Editor

    Published on:

  42. Protein-protein interactions (PPIs) are central to a variety of biological processes, and their dysfunction is implicated in the pathogenesis of a range of human diseases, including cancer. Hence, the inhibiti...

    Authors: Sha-Sha Cheng, Guan-Jun Yang, Wanhe Wang, Chung-Hang Leung and Dik-Lung Ma

    Citation: Journal of Hematology & Oncology 2020 13:26

    Content type: Review

    Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2020 13:102

Annual Journal Metrics

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here